Secondary failure of platelet recovery (SFPR), which is a delayed decline in platelet count after primary recovery following myeloablative hematopoietic SCT, is a significant problem in allogeneic SCT. However, its clinical characteristics have not been well described in autologous SCT for acute myeloid leukemia. We reviewed 11 consecutive patients who had received autologous or syngeneic SCT for acute promyelocytic leukemia. Seven of 11 patients (64%) had SFPR, which is defined as a decline in the platelet count to less than 30 000/ll for more than 7 days. The median onset of SFPR was day 36 (range, 25-51 days) and the median duration of thrombocytopenia was 13 days (range, 4-25 days). Of nine patients who received busulfan-containing preparative regimens, seven (78%) had SFPR and one had delayed primary platelet count recovery. Neither patient who received cyclophosphamide and total body irradiation as preparative regimens had SFPR. The clinical courses of SFPR were transient and self-limited. SFPR was not associated with relapse of underlying diseases, graft failure or other fatal morbidities. The unexpectedly high prevalence and the characteristics of SFPR may provide additional information on management following autologous SCT for acute myeloid leukemia.
Introduction
Thrombocytopenia is a critical problem after myeloablative hematopoietic SCT. [1] [2] [3] [4] [5] Recovery of platelets is affected by several factors, including the stem cell source, the infused cell dose, disease status, graft-versus-host disease, infections, and, especially, CMV. Veno-occlusive disease of the liver (VOD), thrombotic thrombocytopenic purpura/ hemolytic uremic syndrome (TTP/HUS) and allo-immunization to random donor platelets also contribute to thrombocytopenia. [1] [2] [3] 6 A delayed, persistent decline in platelets count after primary platelet recovery is termed secondary failure of platelet recovery (SFPR). Isolated thrombocytopenia may occur without the decline of any other cell lineage. In a large study by Bruno et al., 6 SFPR was observed in 20% of patients undergoing allogeneic transplantation and in 8% of patients undergoing autologous transplantation. Although it is not related to disease recurrence or graft rejection, SFPR is associated with poor outcomes after transplant. Various factors that either affected platelet production in the marrow or caused decreased platelet survival in the peripheral circulation have been implicated in the pathophysiology of SFPR. 1, 3, 6 Autologous HSCT offers favorable outcomes for patients with acute promyelocytic leukemia in the second or later remission with minimal residual disease. 7, 8 We conducted a series of autologous or syngeneic HSCTs for patients with acute promyelocytic leukemia using mobilized PBSCs with granulocyte CSF. An unexpectedly high incidence of SFPR was observed. In this paper, we describe clinical and pathological features that will lead to a new method of SFPR management after HSCT.
Patients and methods

Study patients
We reviewed medical records of 11 consecutive patients who had received autologous or syngeneic HSCT for AML at Nagoya University Hospital, Aichi, Japan, or JA Aichi Showa Hospital, Konan, Japan from 1 April 2000, to 31 December 2004. All patients were evaluated from the day of transplant, defined as day 0, until death or the last routine follow-up.
Transplant procedures
Schedules and doses of preparative regimens are shown in Table 1 . Granulocyte CSF (filgrastim (patients 1-3 and 9-11) or nartograstim (patients 4 and 7-8) was administered intravenously from day 1 until neutrophil engraftment. Sodium valproate 400 mg/day (patients 1-3) or phenytoin 300 mg/day (patients 4-6 and 9-11) were administered for prophylaxis against BU-induced seizure. Prophylaxis against herpes virus infection was administered with acyclovir 1000 mg/day in patients 4-8. Fluoroquinolone and fluconazole or itraconazole were also administered for prophylaxis against bacterial and fungal infections, respectively. Patients 1 and 2 received trimethoprim/sulfamethoxazole for prophylaxis against Pneumocystis jiroveci from day À7 to À1.
Definitions
Primary platelet recovery after myeloablative conditioning regimens was defined as an increase in platelet count to X50 Â 10 3 /ml without transfusion support. SFPR was defined as a decline in the platelet count to less than 30 Â 10 3 /ml for more than 7 days or on two consecutive laboratory examinations, or as the requirement of platelet transfusions after primary platelet recovery. The first day of thrombocytopenia with a platelet count less than 30 Â 10 3 /ml was designated as the onset of SFPR. Neutrophil engraftment was defined as an absolute neutrophil count 40.5 Â 10 9 /l for three consecutive days for neutrophil recovery.
Laboratory examinations
Complete blood cell count and blood chemistry were analyzed 2-3 times a week during hospitalization. Bone marrow aspiration was performed from the sternum to confirm engraftment in all eight patients, and additional examinations were carried out at the onset of SFPR in some patients. CMV pp65 antigenemia 9,10 was analyzed as a method of rapid CMV antigen detection in all patients. The results are reported as the number of antigen-positive cells per slide containing 150 000 polymorphonuclear leukocytes. Platelet-associated immunoglobulin G (PAIgG) was assayed in two patients (patients 4 and 5) around the time of SFPR onset. CMV pp65 antigenemia was monitored weekly after engraftment. CMV antigenemia was managed according to the method reported by Kanda et al.
11 with some modifications. If CMV pp65-positive cells were detected, patients preemptively received ganciclovir (5 mg/kg) two times daily. Ganciclovir could also be started with less than 10 positive cells in the patients who had received more than 0.5 mg/kg of prednisolone.
Statistical analysis
Differences in the incidence of SFPR between patients conditioned with BU-containing regimens and the other Primary platelet recovery after transplantation All 11 patients achieved primary neutrophil engraftment. In all patients, except patient 6, the platelet count was greater than 50 Â 10 3 /ml within 20 days after transplant (range, 10-18 days; median, 14 days). In patient 6, platelet recovery to greater than 50 Â 10 3 /ml did not occur until day 85.
Clinical course of SFPR Seven of 11 patients (64%) had SFPR (patients 1-5, 10 and 11). The median onset of SFPR was day 36 (range, 25-51 days), and the median duration of thrombocytopenia was 13 days (range, 4-25). Platelet counts recovered in all patients developing SFPR ( Table 2 ). None of the seven patients with SFPR showed the decline in WBC count or RBC count during SFPR. Patients 1 and 2 received platelet transfusions. In patient 1, the platelet count declined to 14 Â 10 3 /ml on day 63 and recovered to 47 Â 10 3 /ml on day 70. In patient 6, the primary platelet count recovery did not occur until after day 50, but SFPR was not observed after platelet recovery. Patients 4 and 5 had preceding febrile episode. In patient 10, platelet count declined to 29 Â 10 /ml on day 58. Four of the seven patients with SFPR developed hepatic dysfunction during SFPR (Table 2) . No patients developed renal dysfunctions (Table 2) . No other remarkable clinical manifestations developed in the seven patients during SFPR.
Correlation between SFPR and conditioning regimens or infused cell doses
Of the nine patients who received BU-containing conditioning regimens, that is non-TBI regimens, seven (78%) had SFPR and one (patient 6) had delayed primary recovery of platelet count. Neither patient who received conditioning regimens without BU, that is, CY and TBI, had SFPR (P ¼ 0.067: patient 6 was excluded from analysis because of prolonged thrombocytopenia following transplantation). The median number of infused CD34 þ cells was 3.4 (range, 2.5-9.2) Â 10 6 /kg for patients with SFPR and 3.3 (1.9-4.0) Â 10 6 /kg for patients without SFPR (P ¼ 0.35).
Bone marrow findings
Bone marrow aspiration at the onset of SFPR was performed on day 51 for patient 1, on day 23 for patient 2, on day 20 for patient 3, on day 31 for patient 4 and on day 38 for patient 5. As shown in Figure 1 , all specimens showed normal cellularity, without relapse of leukemia or decrease in the number of megakaryocytes.
CMV antigenemia
In Patient 1, CMV antigenemia (9 positive cells out of 150 000) was detected on day 14, almost at the same time that the stomatitis and fever appeared, and was successfully treated with ganciclovir. In patient 2, the antigenemia was negative on day 23, before onset of SFPR. At day 37, the antigenemia (2 positive cells out of 150 000) was detected at day 37 and it became negative after the administration of ganciclovir. In patients 3-5, the antigenemia was negative at the time of the onset of SFPR. None of the patients had documented CMV diseases. Table 2 shows the outcomes of seven patients with SFPR. Of the seven patients, six are alive without recurrence of leukemia. One patient (patient 5) died of leukemia relapse on day 278.
Outcome of SFPR
Discussion
Here, we have demonstrated a high incidence of SFPR following autologous PBSC transplantation (PBSCT) for AML. Bruno et al. 6 have reported a low incidence (3.8%) of SFPR after autologous SCT. 12 Unlike their study, in which the 1-year mortality of patients with SFPR was high (44%), in our study SFPR was self-limiting and did not affect the relapse of underlying diseases. The different feature from their report was that SFPR in our patients were self limiting and did not affect the relapse of underlying disease; in contrast the 1-year mortality of patients developing SFPR was relatively high (44 %) in their study. This contrast might be due to differences in patient profiles.
A high prevalence (64%) of SFPR was consistently observed in our patients with AML who received autologous PBSCT. One report has shown that 5 (56%) of 9 patients with AML had SFPR, whereas 16 (11%) of 146 patients with diseases other than AML who received autologous PBSCT had secondary thrombocytopenia. 1 Underlying disease of AML was a statistically significant predictor of poor platelet engraftment after both autologous BMT and PBSCT, compared with transplants for SFPR after autologous-SCT H Narimatsu et al Table 2 Clinical and laboratory findings of the patients with SFPR Patient no. other diseases. 6 Previous intensive chemotherapy for AML before PBSC harvest might deplete the primitive precursor cells that maintain long-term hematopoiesis.
Onset of SFPR
Interestingly, seven of nine patients receiving BUcontaining conditioning regimens had SFPR, whereas neither patient receiving TBI-based regimens had SFPR, although the difference was not statistically significant. The BU-containing regimen has particularly been used in transplants in patients with myeloid malignancies, and has been suggested to be associated with the development of VOD. Although VOD was not clinically evident in our patients, BU may have injured endothelial cells to induce platelet activation and sequestration resulting in subclinical VOD or TTP/HUS.
The elevation of PA-IgG in patients 4 and 5, and the preceding febrile episodes of possibly infectious origins in patients 1 and 3 suggest immunomediated thrombocytopenia. Bone marrow megakaryocytes did not decrease in any patients during SFPR. Auto-immune thrombocytopenia after high-dose chemotherapy and autologous BMT/ PBSCT has been reported, but occurs infrequently in patients with AML, lymphoblastic lymphoma or breast cancer. [13] [14] [15] [16] [17] [18] Although the exact mechanism for the development of autoimmune thrombocytopenia is unknown, several possible mechanism have been proposed including transient immune system perturbation, such as impaired suppressor T-cell function, immune deregulation related to thymic damage caused by irradiation and chemotherapy, and altered expression of self antigens as a result of stem cell damage during harvest and storage and viral infections after transplant. 13, 18 Serum cytokine profiles observed in immunological imbalances might contribute to the activation of monocytes and macrophages, which are critical components in the elimination pathway of platelets. 1 Thus, immunological perturbations following transplants possibly caused decreased platelet survival by activating the elimination system in the peripheral circulation.
CMV infection after primary platelet recovery was most significantly associated with the incidence of SFPR in a previous report. 6 In the present study, CMV disease was not documented in any patient. Moreover, preemptive ganciclovir use was not related to the onset of SFPR or to clinical outcome. Thus, although CMV infection is a potential cause of SFRR, it was not involved in our series.
In summary, SFPR was observed frequently after autologous and syngeneic transplantation in patients with acute promyelocytic leukemia. The high prevalence of SFPR may be related to the use of PBSC as a stem cell source and the use of BU-containing preparative regimens. While multiple mechanisms are involved in the development of SFPR, the identification of etiology in each patient with precise descriptions of clinical characteristics should improve patient care.
